CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

High-cost multivitamin prior authorization policy

Defines prior authorization requirements for multivitamin prescriptions above a $50 per-fill maximum cost edit for Neighborhood Health Plan of Rhode Island Medicaid FIDE SNP members. Affects pharmacy claims adjudication and prescribing providers.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyHigh-cost multivitamin prior authorization policy

Policy CodePolicy N/A

Change TypeMaximum cost edit implemented

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization for multivitamin fills with a cost per fill above $50 by documenting trials of three formulary alternatives and submitting supporting clinical evidence.

SourceLink

POLICY UPDATE CHANGES

A maximum cost edit was implemented for multivitamin preparations such that fills under $50 adjudicate without authorization while fills above $50 require prior authorization.

$50max cost without auth

$1.39avg cost per fill

>=5xthreshold vs avg

12max coverage duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Initial Authorization

Covered when ALL of the following are met

Initial authorization criteria

A. The requested drug/product is being used per the product's labeling or for an FDA-approved indication or a medically accepted indication as defined in AHFS-DI, Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or peer-reviewed published medical literature.
B. The prescribed dose and quantity fall within the product's labeling or within FDA- or compendia-supported dosing guidelines.
C. The member has tried and failed at least 3 formulary alternative multivitamin preparations; documentation of the tried and failed alternatives must be submitted.
D. The prescriber has submitted clinical evidence (e.g., published comparative study results) showing that the requested high-cost multivitamin preparation is clinically superior to at least one of the tried and failed formulary alternatives.

Initial therapy: See Initial Authorization criteria I.A–I.D: indication per labeling/compendia, appropriate dose/quantity, failure of >=3 formulary alternatives, and clinical evidence of superiority.

Authorization up to 12 months if approved.

Continuation of Therapy

Covered when ALL of the following are met

Continuation criteria: Patient meets all initial criteria in section I.

Continuation approvals rely on persistence of initial approval criteria.

Fills with a cost per fill of $50 or less are excluded from prior authorization and will adjudicate at point-of-sale without requiring prior approval. Any multivitamin fill with a reported cost per fill greater than $50 will reject at point-of-sale due to the maximum cost edit and will require submission of a prior authorization request.

Initial Therapy

Initial authorization requirement for high-cost multivitamin fills (> $50 per fill)

High-cost multivitamin initial therapy: Authorization requires meeting all Initial Authorization criteria I.A–I.D: use per labeling or a medically accepted indication, dose/quantity within labeling or compendia-supported dosing, documentation of trial and failure of ≥3 formulary alternative multivitamin preparations, and submission of clinical evidence demonstrating superiority over at least one tried alternative.

Prior authorization is required for fills with cost per fill above the $50 maximum cost edit; approvals may be granted up to 12 months when criteria met.

Continuation Therapy

Continuation authorization requirement

Continuation: Patient meets all initial criteria in section I.

Continuation approvals valid up to the coverage duration.

Provider Actions & Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for multivitamin prescriptions with a cost per fill above $50. Claims with a per‑fill cost greater than $50 will reject at point‑of‑sale under Neighborhood's maximum cost edit and will not adjudicate without an approved prior authorization.

Cost threshold: $50 per fill
Point‑of‑sale rejection triggers prior authorization requirement

Step Therapy

Required Failures of Formulary Alternatives

Members must have tried and failed at least three formulary alternative multivitamin preparations before a high‑cost multivitamin authorization will be approved. The prescriber must document each trial and the reason for failure (for example: lack of efficacy, adverse reaction, intolerance, allergy, or nonresponse).

Minimum required failures: 3 formulary alternatives
Document reason for each failure (efficacy, adverse reaction, intolerance, allergy, nonresponse)

Coding & Cost Edit

Maximum cost edit per fill

Maximum cost edit per fill$50 per fill — fills at or below this amount adjudicate at the pharmacy without prior authorization; fills above $50 will reject at point-of-sale and require prior authorization.

Rationale for thresholdSet at least five times the 2024–2025 average multivitamin fill cost (average $1.39, excluding fills > $1,000) to prevent fraud, waste & abuse while preserving access to clinically necessary formulations.

Effective applicationApplies to multivitamin preparations processed by Neighborhood's Pharmacy Department beginning in 2026.

Step Therapy Requirements

Step requirement	Required documentation
Trial and failure of at least three formulary alternative multivitamin preparations
Documentation of each tried and failed alternative (e.g., medication names, dates of trial, reason for failure) must be submitted
Use per product labeling or FDA/medically accepted indication as defined by listed compendia
Evidence that the requested product is used per labeling or a medically accepted indication (reference to AHFS‑DI, DrugDex, Clinical Pharmacology, Lexi‑Drugs, or peer‑reviewed literature)
Prescribed dose and quantity within labeling or compendia‑supported dosing
Prescription details confirming dose and quantity fall within product labeling or FDA/compendia dosing guidelines
Clinical evidence of superiority over at least one tried alternative
Attach clinical evidence (e.g., published comparative study results) demonstrating the requested high‑cost multivitamin is clinically superior to at least one tried and failed formulary alternative

Definitions

Medically accepted indication (definition)

Definition source listMedically accepted indication as defined by any one of the following: AHFS-DI, Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or peer-reviewed published medical literature.

Usage requirementRequested product must be used per product labeling or for an FDA-approved or compendia-supported medically accepted indication.

Evidence standardPeer-reviewed published medical literature must demonstrate sufficient evidence to support use when relied upon for a medically accepted indication.

Background

Neighborhood implemented a maximum cost edit on multivitamin preparations to reduce fraud, waste, and abuse (FWA) while preserving access to clinically necessary, higher-cost formulations. The cost threshold was set after utilization review of 2024–2025 claims data: the average multivitamin fill cost (excluding extreme outliers > $1,000) was approximately $1.39, and the threshold was chosen to be at least five times that average so that routine low-cost fills adjudicate without authorization but higher-cost fills undergo clinical review. Under this policy, fills above the $50 per fill limit will reject and require prior authorization to ensure appropriate medical necessity and documented justification.

Revision History

2026-01-01effective_dateLatest

Policy effective date; a maximum cost edit of $50 per fill for multivitamin preparations implemented such that fills at or below $50 adjudicate without prior authorization while fills above $50 require prior authorization (material change).

2026implementation_note

Maximum cost edit operationalized for 2026 based on 2024–2025 utilization analysis to prevent fraud, waste, and abuse while allowing access to certain injectable formulations.